Infection Management Coalition

About the IMC

The Infection Management Coalition (IMC) is a group of charities, professional societies, industry bodies and life science companies that have come together to advocate for a holistic approach to infection management to better protect our citizens, healthcare system and economy.

Our aim is to improve infection prevention, diagnosis and treatment, alongside comprehensive support for people affected by infection. Through our wide-ranging membership, we have access to expertise and information that can support the implementation of a more comprehensive and coordinated approach to infection.

We firmly believe in our collaborative multi-stakeholder approach to break down siloes in the system and support the UK Government’s ambitions to tackle challenges in antimicrobial resistance, sepsis and pandemic preparedness.

Our Ambition

The IMC hopes to support the development of cohesive policy and deliver immediate and long-term change for the better. This means working collectively to publish infection management plans that include plans for AMR; resourcing all areas equally; creating a task force of stakeholders with equal voices; implementing an infection registry with patient level data and real-time tracking; ensuring valued consideration of the antimicrobial and diagnostics pipeline and delivering systems integration of infection management.

We have outlined our call to action within our White Paper (see below) alongside our supporting recommendations as a first step to achieve our collective aim of delivering transformational change that aligns to government policy and will benefit the NHS in delivery of effective patient treatment.

From our founding in 2021 and beyond, we have been and are continuing to focus on driving forward our recommendations and enabling policy change. Further detail on our work can be found below.

Globally, there are 4.95 million deaths per year associated with AMR1 and no new classes of antibiotics have been discovered since the 1980s.2 The time to act is now.

Infection Management Coalition Members

Gold Members

Bronze Members

Associate Members

Secretariat provided by Hanover Communications

For more information, please contact imc@hanovercomms.com

Key facts

Our work

Parliamentary engagement

IMC Parliamentary Event - July 2022

Conferences

King’s Fund Annual Conference 2023 – November 2023

Speaker slots

Infection Prevention and Control Conference (IPC) 2023 – April 2023

Lee Durnall (Menarini), Doris- Ann Williams MBE (former BIVDA), and Jonathan Pearce (Antibiotic Research UK) speaking at the IPC Conference 2023 to 127 attendees about the IMC.

Industry awards

Contact us

If you would like to find out more about our work, or would be interested in joining the coalition, please contact Hanover Communications (IMC Secretariat): imc@hanovercomms.com

The IMC Whitepaper & our key priorities

We launched our Whitepaper in February 2022, the first of its kind to outline detailed recommendations for holistic infection management. It sets out a bold vision for improved surveillance, prevention, screening, diagnosis, management and reporting of infection, paired with comprehensive support for people affected by infection and their families.

The IMC has identified four priority recommendations on the basis of their urgency, feasibility and impact.

Click here to download the report

Coalition member statements

    For more information, please contact IMC@hanovercomms.com

    Date of prep: August 2024

    NP-NP-UK-0012 (content)
    NP-NP-UK-0013 (link)

    Compliance review of this website has been undertaken by A. Menarini Farmaceutica Internazionale SRL and bioMérieux UK Ltd.

    References

    1. World Health Organization. Vaccines could avert half a million deaths associated with anti-microbial resistance a year. Available at: https://www.who.int/news/item/28-07-2023-vaccines-could-avert-half-a-million-deaths-associated-with-anti-microbial-resistance-a-year.
      Last accessed: January 2024.
    2. Wellcome Trust. Why is it so hard to develop new antibiotics?. Available at: https://wellcome.org/news/why-is-it-so-hard-develop-new-antibiotics.
      Last accessed: January 2024.
    3. World Health Organization. The true death toll of COVID-19: estimating global excess mortality. Available at: https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality.
      Last accessed: January 2024.
    4. Gov.UK. Health matters: antimicrobial resistance. Available at: https://www.gov.uk/government/publications/health-matters-antimicrobial-resistance/health-matters-antimicrobial-resistance.
      Last accessed: January 2024.
    5. Llor C. and Lars B,. (December 2014). Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232501/.
      Last accessed: January 2024.
    6. World Health Organization. Antimicrobial resistance. Available at: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
      Last accessed: January 2024.
    7. World Health Organization. Antimicrobial resistance. Available at: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
      Last accessed: January 2024.
    8. University of Oxford. An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections. Available at: https://www.ox.ac.uk/news/2022-01-20-estimated-12-million-people-died-2019-antibiotic-resistant-bacterial-infections.
      Last accessed: January 2024.
    9. The UK Sepsis Trust. References and sources. Available at: https://sepsistrust.org/about/about-sepsis/references-and-sources/.
      Last accessed: January 2024
    10. The UK Sepsis Trust. The Sepsis Manual 4th Edition 2017-2018. Available at: https://www.e-lfh.org.uk/wp-content/uploads/2018/02/Sepsis_Manual_2017_final_v7.pdf.
      Last accessed: January 2024
    brand-1 brand-2